Supportive Care Evidence Shaping COPERNICUS: Lessons From PALOMA three, COCOON, and SKIPPirr

This section focuses on the key supportive care studies that directly informed the design of COPERNICUS. Dr Santos reviews PALOMA three, COCOON, and SKIPPirr, highlighting how each addressed specific tolerability and delivery challenges associated with amivantamab based therapy.

PALOMA three evaluated the subcutaneous formulation of amivantamab and demonstrated pharmacokinetic equivalence to intravenous administration, along with fewer administration related reactions and reduced clinic time. These findings provided the foundation for adopting subcutaneous delivery in COPERNICUS. COCOON addressed dermatologic toxicity, showing that proactive prophylaxis significantly reduced moderate to severe skin adverse events. This marked a shift from reactive management to prevention, which Dr Santos describes as essential when using dual EGFR inhibition.

SKIPPirr examined the use of dexamethasone to prevent infusion related reactions during early treatment. The study demonstrated a substantial reduction in these reactions, supporting early prophylaxis rather than treatment interruption. Dr Santos emphasizes that together, these studies highlight the importance of integrating supportive care strategies upfront.

By embedding these evidence based interventions into COPERNICUS, the study aims to improve tolerability, adherence, and long term treatment success. This section reinforces the idea that supportive care is not secondary to efficacy but a central component of effective cancer therapy in real world settings.